Virus-like particles: The new frontier of vaccines for animal viral infections

被引:110
|
作者
Crisci, Elisa [1 ]
Barcena, Juan [2 ]
Montoya, Maria [1 ,3 ]
机构
[1] UAB IRTA, Ctr Recerca Sanitat Anim CReSA, Barcelona 08193, Spain
[2] Ctr Invest Sanidad Anim CISA INIA, Madrid 28130, Spain
[3] IRTA, Barcelona, Spain
关键词
Virus-like particles (VLPs); Animal vaccines; Vaccine vectors; RABBIT HEMORRHAGIC-DISEASE; PORCINE CIRCOVIRUS TYPE-2; PARVOVIRUS-LIKE PARTICLES; ROTAVIRUS-LIKE PARTICLES; TOBACCO-MOSAIC-VIRUS; T-CELL RESPONSES; IMMUNE-RESPONSES; CAPSID PROTEIN; PROTECTIVE IMMUNITY; CANINE PARVOVIRUS;
D O I
10.1016/j.vetimm.2012.04.026
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccination continues to be the main approach to protect animals from infectious diseases. Until recently, all licensed vaccines were developed using conventional technologies. Subunit vaccines are, however, gaining attention from researchers in the field of veterinary vaccinology, and among these, virus-like particles (VLPs) represent one of the most appealing approaches. VLPs are robust protein cages in the nanometer range that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines. Here, we review the current status of VLPs as a vaccine technology in the veterinary field, and discuss the potential advantages and challenges of this technology. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:211 / 225
页数:15
相关论文
共 50 条
  • [1] Norwalk virus-like particles as vaccines
    Herbst-Kralovetz, Melissa
    Mason, Hugh S.
    Chen, Qiang
    EXPERT REVIEW OF VACCINES, 2010, 9 (03) : 299 - 307
  • [2] Bioengineering Virus-Like Particles as Vaccines
    Lua, Linda H. L.
    Connors, Natalie K.
    Sainsbury, Frank
    Chuan, Yap P.
    Wibowo, Nani
    Middelberg, Anton P. J.
    BIOTECHNOLOGY AND BIOENGINEERING, 2014, 111 (03) : 425 - 440
  • [3] Virus-Like Particles as Particulate Vaccines
    Buonaguro, Luigi
    Tornesello, Maria L.
    Buonaguro, Franco M.
    CURRENT HIV RESEARCH, 2010, 8 (04) : 299 - 309
  • [4] Production of virus-like particles for vaccines
    Fuenmayor, J.
    Godia, F.
    Cervera, L.
    NEW BIOTECHNOLOGY, 2017, 39 : 174 - 180
  • [5] The application of virus-like particles as vaccines and biological vehicles
    Yan, Dan
    Wei, Yan-Quan
    Guo, Hui-Chen
    Sun, Shi-Qi
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2015, 99 (24) : 10415 - 10432
  • [6] Use of plant viruses and virus-like particles for the creation of novel vaccines
    Balke, Ina
    Zeltins, Andris
    ADVANCED DRUG DELIVERY REVIEWS, 2019, 145 : 119 - 129
  • [7] Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections
    Ren, Mei
    Abdullah, Sahibzada Waheed
    Pei, Chenchen
    Guo, Huichen
    Sun, Shiqi
    VETERINARY RESEARCH, 2024, 55 (01)
  • [8] Virus-like particles produced in plants as potential vaccines
    Scotti, Nunzia
    Rybicki, Edward P.
    EXPERT REVIEW OF VACCINES, 2013, 12 (02) : 211 - 224
  • [9] Plant-derived virus-like particles as vaccines
    Chen, Qiang
    Lai, Huafang
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (01) : 26 - 49
  • [10] Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
    Tornesello, Anna Lucia
    Tagliamonte, Maria
    Buonaguro, Franco M.
    Tornesello, Maria Lina
    Buonaguro, Luigi
    VACCINES, 2022, 10 (02)